Loading...
•
Mar 31, 2022
Sana Q1 2022 Earnings Report
Sana Biotechnology reported financial results and business highlights
Key Takeaways
Sana Biotechnology reported a net loss of $31.4 million, or $0.17 per share, for the first quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $657.4 million as of March 31, 2022. Significant progress was made towards clinical trials for programs across multiple platforms.
Advanced towards clinical trials for ex vivo hypoimmune allogeneic CAR T and in vivo fusogen CAR T programs.
Remain on track to file INDs for both ex vivo hypoimmune allogeneic CAR T and in vivo fusogen CAR T programs this year.
Expanded CAR T capability to potentially develop best-in-class, broadly accessible CAR T cell therapies.
Presented preclinical data at the 2022 American Association for Cancer Research Annual Meeting.
Sana
Sana
Forward Guidance
Sana Biotechnology expects to file INDs this year for ex vivo hypoimmune allogeneic CAR T and in vivo fusogen CAR T.